about
DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelPRL-3 phosphatase is implicated in ovarian cancer growthPhospholipase Cgamma1 is required for metastasis development and progressionChemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial dataP73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer.Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3',4',5'-trimethoxyflavonol, a quercetin analogue.Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cellsDirect but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastasesDevelopment of distamycin-related DNA binding anticancer drugs.Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker.p73: a chiaroscuro gene in cancer.Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.Triple negative breast cancers have a reduced expression of DNA repair genesGenetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients.Microsatellite instability and genetic alterations in ovarian cancer.Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cellsCell cycle checkpoint proteins and cellular response to treatment by anticancer agents.New molecules and strategies in the field of anticancer agents.Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell LinesImproving the selectivity of cancer treatments by interfering with cell response pathways.L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivativesRole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyBase excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerEffect of Aplidin in acute lymphoblastic leukaemia cells.Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver.Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.PI3K/AKT/mTOR inhibitors in ovarian cancer.Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.
P50
Q24339462-B975A5D6-6E9B-43DC-AD10-15A06AC9E865Q27302940-8C8DA60E-86C7-451D-AE18-6E0DA4AB5FE7Q28275403-3595A068-F0CF-4639-A861-82E1A612D158Q28303679-DF7D4419-9C55-4BA9-AACB-A2A4092FAD98Q30940337-3564D59D-6244-4A36-BF5E-1D5E0C9645D7Q32061496-C29C2D34-98A7-493D-B11B-9C7B7846F315Q33612929-4E5EC570-6122-417F-B787-B38B5AF14BEDQ33918755-B5A51D9F-0434-4D07-96FC-EA937BE211F3Q33952827-4C547175-6869-4EB3-9210-07E9B1E93542Q34051278-FBB86E68-B709-4BAA-B041-3AF8DDAF9C2AQ34104005-30728589-D418-4AF7-87C4-D4530A1DC237Q34168295-B6B8EC3B-EDF7-4DA7-84A8-7E3537674087Q34202863-53B49BB9-E57B-4C0B-8917-E67C21CC0C20Q34423130-73D82C57-2D57-4D0F-BB9C-77305DDF41E4Q34481722-1579B8C2-695F-409F-9F6A-0DF628689982Q34611461-A1E35AFA-5400-4901-B79E-46EABDFA6ECEQ34618259-0E35D620-FFDE-44EF-BB34-95CEF4B065A7Q34785151-55939558-CD87-48A1-86AA-26C0F2F73E52Q34794035-FD28737E-B93A-4EBF-95F4-F774DB076348Q34813092-F1C294A7-FB7B-414C-A526-6D16E1911FCDQ35113646-0622A06D-7F17-451B-B12C-15D6A6EAA8FDQ35206753-101AE306-2706-4321-8055-AE42F71209AEQ35601104-373A3A28-4DC1-4556-BF34-9321DD1B8EFFQ35768346-C2942BCC-BE96-4BC4-AE5C-77E3CFD482CEQ35802653-47499A44-5C62-4890-9A82-70880DCF1412Q35804653-03D2EE92-EE16-40B3-A20A-8650488C6B51Q35889951-A1EB400F-7D73-4A6A-9245-61A549AB0BDCQ35948054-37F5E9FD-2996-413F-943E-0B78D519FA84Q35977659-7875C165-8811-491D-9CF1-20DFEE311DADQ36287562-C576E091-2F7B-4238-ADDB-5526DCABE5DEQ36430931-BCB052D7-BCE0-4F84-B233-994D075F49FFQ36545375-387FD3AF-B2B8-48FF-8970-2A1664AF083CQ36557507-B7EA39F7-8C93-4D36-8D70-D74D9AEDDFF1Q36574080-3DAA418B-EBA0-45CD-A50C-C3C11B509A6DQ36648269-8B2DF799-BB4E-4DE3-B1C2-BBAB4E84B65FQ37092677-76253A65-1D10-44AD-82E2-EF52DDEF8E7DQ37109753-E1507828-BD2D-4F6A-B31C-0DB6A4E36913Q37378689-1E7274F4-E3C0-40BD-A80E-5C93DB8C0FFFQ37808253-C272FD5F-C472-4769-B4B6-9209399B2A95Q37961283-2B14D5C2-69F7-4278-B28C-FA902EF830C0
P50
description
researcher ORCID ID = 0000-0002-8138-9358
@en
wetenschapper
@nl
name
Massimo Broggini
@ast
Massimo Broggini
@en
Massimo Broggini
@es
Massimo Broggini
@nl
type
label
Massimo Broggini
@ast
Massimo Broggini
@en
Massimo Broggini
@es
Massimo Broggini
@nl
prefLabel
Massimo Broggini
@ast
Massimo Broggini
@en
Massimo Broggini
@es
Massimo Broggini
@nl
P106
P1153
7006243192
P31
P496
0000-0002-8138-9358